Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) will be hosting a conference call at 4:30 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community.
A live webcast with presentations will be available on the Internet by visiting the Company website www.marinuspharma.com
Earnings Expectation
Marinus Pharmaceuticals, Inc. is expected to report third quarter earnings results, after market close, on Monday 9th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.6 per share from revenue of $ 0.42 million. Looking ahead, the full year loss are expected at $ 2.81 per share on the revenues of $ 3.16 million.
Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The companys ganaxolone product candidate exhibits anti-seizure, anti-depression, and anti-anxiety actions through its effects on synaptic and extrasynaptic GABAA receptors.
